NASDAQ:PAHC - Phibro Animal Health Stock Price, Forecast & News

Phibro Animal Health trades on the NASDAQ under the ticker symbol "PAHC."

Phibro Animal Health declared a quarterly dividend on Monday, November 4th. Shareholders of record on Wednesday, November 27th will be paid a dividend of $0.12 per share on Wednesday, December 18th. This represents a $0.48 dividend on an annualized basis and a yield of 1.85%. The ex-dividend date of this dividend is Tuesday, November 26th. View Phibro Animal Health's Dividend History.

Phibro Animal Health Corp (NASDAQ:PAHC) announced its earnings results on Monday, November, 4th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.24 by $0.05. The company had revenue of $190 million for the quarter, compared to the consensus estimate of $199.22 million. Phibro Animal Health had a return on equity of 25.52% and a net margin of 4.99%. The firm's quarterly revenue was down 5.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.39 earnings per share. View Phibro Animal Health's Earnings History.

Phibro Animal Health is scheduled to release their next quarterly earnings announcement on Monday, February 3rd 2020. View Earnings Estimates for Phibro Animal Health.

Phibro Animal Health will be holding an earnings conference call on Monday, February 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Phibro Animal Health updated its FY20 earnings guidance on Monday, November, 4th. The company provided earnings per share guidance of $1.08-$1.14 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.12.

5 brokers have issued 12-month price targets for Phibro Animal Health's stock. Their forecasts range from $18.00 to $42.00. On average, they anticipate Phibro Animal Health's stock price to reach $27.60 in the next year. This suggests a possible upside of 6.2% from the stock's current price. View Analyst Price Targets for Phibro Animal Health.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phibro Animal Health in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Phibro Animal Health.

News articles about PAHC stock have been trending positive on Tuesday, InfoTrie reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Phibro Animal Health earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Phibro Animal Health.

Phibro Animal Health saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 778,200 shares, an increase of 7.1% from the December 15th total of 726,300 shares. Based on an average daily volume of 171,600 shares, the short-interest ratio is presently 4.5 days. Currently, 3.9% of the shares of the company are short sold. View Phibro Animal Health's Current Options Chain.

Some companies that are related to Phibro Animal Health include Evotec (EVTCY), United Therapeutics (UTHR), Allakos (ALLK), Nektar Therapeutics (NKTR), FibroGen (FGEN), Mirati Therapeutics (MRTX), SAGE Therapeutics (SAGE), GW Pharmaceuticals PLC- (GWPH), Deciphera Pharmaceuticals (DCPH), Ultragenyx Pharmaceutical (RARE), Blueprint Medicines (BPMC), PTC Therapeutics (PTCT), Zai Lab (ZLAB), Myokardia (MYOK) and Taro Pharmaceutical Industries (TARO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Phibro Animal Health investors own include Zynga (ZNGA), Trevena (TRVN), Endo International (ENDP), Intercept Pharmaceuticals (ICPT), Sonoma Pharmaceuticals (SNOA), Zynerba Pharmaceuticals (ZYNE), Zoetis (ZTS), Booking (BKNG), Banco Bradesco (BBD) and Gilead Sciences (GILD).

Phibro Animal Health's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Tocqueville Asset Management L.P. (0.70%), Bridge City Capital LLC (0.19%), Dupont Capital Management Corp (0.16%), California Public Employees Retirement System (0.11%), Nisa Investment Advisors LLC (0.07%) and Arizona State Retirement System (0.03%). Company insiders that own Phibro Animal Health stock include Bfi Co, Llc, Daniel M Bendheim, Dean J Warras, E Thomas Corcoran, Jack Bendheim and Larry Lee Miller. View Institutional Ownership Trends for Phibro Animal Health.

PAHC stock was sold by a variety of institutional investors in the last quarter, including Arizona State Retirement System and California Public Employees Retirement System. View Insider Buying and Selling for Phibro Animal Health.

PAHC stock was acquired by a variety of institutional investors in the last quarter, including Dupont Capital Management Corp, Bridge City Capital LLC, Nisa Investment Advisors LLC and Tocqueville Asset Management L.P.. View Insider Buying and Selling for Phibro Animal Health.

Shares of PAHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PAHC stock can currently be purchased for approximately $26.00.

Phibro Animal Health has a market capitalization of $1.05 billion and generates $828 million in revenue each year. The company earns $54.71 million in net income (profit) each year or $1.53 on an earnings per share basis. Phibro Animal Health employs 1,600 workers across the globe.View Additional Information About Phibro Animal Health.

The official website for Phibro Animal Health is http://www.pahc.com/.

Phibro Animal Health's mailing address is GLENPOINTE CENTRE EAST 3RD FLOOR 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ, 07666. The company can be reached via phone at 201-329-7300 or via email at [email protected]